Costa Mafalda, Lopes Fernandes Catarina, Magalhães Helena
Medical Oncology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, Portugal.
Cancers (Basel). 2024 Dec 1;16(23):4036. doi: 10.3390/cancers16234036.
Gastric cancer is the fifth most common cancer worldwide and its incidence is rising. Surgery is the only curative strategy and its association with perioperative chemotherapy is now standard treatment for most resectable tumors. Despite treatment advances, disease relapse is high, even in early stages, and continued improvement in curative treatment is imperative. With deeper knowledge of gastric cancer heterogeneity, molecular subtypes, and the tumor immune microenvironment, new standard treatment strategies may emerge in the near future. This paper provides a comprehensive review of the current treatment landscape in resectable gastric cancer and future perspectives for the next decade regarding new agents such as targeted therapies, immunotherapy, antibody-drug conjugates, and the combination of multiple treatment modalities.
胃癌是全球第五大常见癌症，其发病率正在上升。手术是唯一的治愈性策略，目前对于大多数可切除肿瘤而言，手术联合围手术期化疗是标准治疗方法。尽管治疗取得了进展，但即使在早期阶段，疾病复发率仍很高，因此必须持续改进根治性治疗。随着对胃癌异质性、分子亚型和肿瘤免疫微环境的深入了解，新的标准治疗策略可能在不久的将来出现。本文全面综述了可切除胃癌的当前治疗格局以及未来十年针对靶向治疗、免疫治疗、抗体药物偶联物等新药物以及多种治疗方式联合应用的未来展望。
